Sign In
Buy NVO
$47.64
+0.230 (+0.485%)
At Close: Jun 25, 2026
Novo Nordisk's Moat Is Deeper Than You Think
10:03am, Tuesday, 22'nd Jul 2025
Novo Nordisk holds 72% international and 50%+ U.S. market share in GLP-1 treatments, serving 46 million patients globally. Obesity drug sales surged 65% YoY in Q1-FY25, driving total revenue growth of
2 Beaten-Down Dividend Growth Stocks to Buy on the Dip
05:57am, Tuesday, 22'nd Jul 2025
A stock market that keeps reaching all-time highs hardly seems like anything for investors to complain about. But if you're trying to build a growing stream of passive income, extended bull markets ar
Novo Nordisk (NYSE: NVO) Stock Price Prediction and Forecast 2025-2030 (July 2025)
08:25am, Monday, 21'st Jul 2025
Among all the weight loss drugs, Ozempic has become a phenomenon. With as much as $17 billion in sales in 2024 and almost $5 billion in the first quarter of 2025, it shows no signs of slowing down, mu
2 Undervalued Healthcare Stocks Poised to Dominate the Next Decade
08:15am, Monday, 21'st Jul 2025
Pharmaceutical giants Pfizer (PFE -0.45%) and Novo Nordisk (NVO -1.50%) have lagged the market over the past year, although Pfizer's poor performance dates back much further. Though these companies ha
A Once-in-a-Lifetime Opportunity: This Blue Chip Healthcare Stock Down 50% Could Double Your Money
09:24pm, Sunday, 20'th Jul 2025
Investors looking to strike while the iron is hot can buy beaten-down stocks that appear to have excellent chances of bouncing back. And that describes shares of Novo Nordisk (NVO -1.50%) very well.
Fangzhou and Novo Nordisk Signed Collaboration Memorandum to Establish a New Ecosystem for Health Management
08:00pm, Sunday, 20'th Jul 2025
Fangzhou Inc., a leader in Internet healthcare solutions, signed a Memorandum of Understanding with Novo Nordisk, a leading global healthcare company.
Weight loss drugs could be a gamechanger for women with a common hormonal disorder
08:00am, Sunday, 20'th Jul 2025
Several women who have reported improvements in symptoms of polycystic ovary syndrome, a common hormonal disorder, after using GLP-1s such as Novo Nordisk's Wegovy and Eli Lilly's Zepbound. Patients a
Novo Nordisk Has So Much Room To Go
06:33am, Sunday, 20'th Jul 2025
Novo Nordisk's Q1 2025 results were solid, but FY guidance was cut, suggesting a longer recovery. Large growth potential exists, with 85% of diabetes patients undertreated and obesity treatments under
Can Wegovy & Ozempic Drive Another Strong Quarter for Novo Nordisk?
10:41am, Friday, 18'th Jul 2025
Wegovy and Ozempic drive 66% of NVO's Q1 revenues - investors eye Q2 sales ahead of results on Aug. 6.
Fangzhou and Novo Nordisk Signed Collaboration Memorandum to Establish a New Ecosystem for Health Management
08:04am, Friday, 18'th Jul 2025
BEIJING , July 18, 2025 /PRNewswire/ -- Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leader in Internet healthcare solutions, signed a Memorandum of Understanding with Novo Nordisk, a lea
3 Ridiculously Discounted Growth Stocks to Buy Now
10:55am, Wednesday, 16'th Jul 2025
Key Points in This Article: Buying beaten-down stocks allows investors to purchase high-quality companies at bargain prices, capitalizing on market overreactions.
Novo Nordisk Plunges 20% YTD: How Should Investors Play the Stock?
09:36am, Tuesday, 15'th Jul 2025
NVO shares fall 19.9% year to date amid weak CagriSema data, CEO exit and rising pressure from rivals in obesity care.
3 Absurdly Cheap Growth Stocks to Load Up On Right Now
03:33am, Tuesday, 15'th Jul 2025
Buying stocks that are trading at cheap valuations can set you up for some big gains later on. And it can minimize the risk of a decline if the market starts to struggle.
3 Dividend Growth Stocks to Turn $10,000 Into $50,000 by 2035
10:18am, Monday, 14'th Jul 2025
These dividend stocks have high dividend growth rates and good yields. The underlying stock also has solid upside potential.
Investors Heavily Search Novo Nordisk A/S (NVO): Here is What You Need to Know
10:00am, Monday, 14'th Jul 2025
Novo Nordisk (NVO) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
